The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca

Inclusion Criteria: * Healthy male subjects age 19 to 55 at the screening visit * Body weight≥50kg and within Ideal body weight±20% * Subject who is judged to be eligible according to clinical laboratory tests including hematological examination, blood chemistry examination, urine analysis * Subject who volunteerly determined to participate in and agreed to comply with precautions after totally understand the detailed explanations about this study Exclusion Criteria: * Subject with serious active cardiovascular, respiratory, hepatology, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease * Subject with symptoms of acute disease within 28days prior to study medication dosing * Subject with known for history which affect on the absorption, distribution, metabolism or excretion of drug * Subject with clinically significant active chronic disease * Subject with any of the following conditions in laboratory test i. AST(aspartate aminotransferase) or ALT(alanine transferase) \> upper normal limit × 1.5 ii. Total bilirubin \> upper normal limit × 1.5 iii. renal failure with Creatinine clearance \< 50mL/min iv. creatine phosphokinase \> upper normal limit × 2 * Positive test results for hepatitis B virus surface antigen, anti-hepatitis C virus antibody, human immunodeficiency virus antigen/antibody,venereal disease research laboratory test * Use of any prescription medication within 14 days prior to study medication dosing * Use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing * Subject with clinically significant allergic disease (except for mild allergic rhinitis and mild allergic dermatitis that are not needed to administer drug) * Subject with known for hypersensitivity reaction to fenofibrate, fenofibric acid or statin * gallbladder disease * Subject who experiences photo-allergy or photo-toxicity during administrating fibrates or ketoprofen * Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption * Subject who is not able to taking the institutional standard meal * Subject with whole blood donation within 60days, component blood donation within 20days * Subjects receiving blood transfusion within 30days prior to study medication dosing * Participation in any clinical investigation within 60days prior to study medication dosing * Continued excessive use of caffeine (caffeine \> five cups/day), alcohol(alcohol\>30g/day) and severe heavy smoker(cigarette \> 10 cigarettes per day) * Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator